Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 113.29B |
| Revenue (ttm) | 23.16B |
| Net Income (ttm) | 8.71B |
| Shares Out | 61.55M |
| EPS (ttm) | 137.33 |
| PE Ratio | 13.40 |
| Forward PE | 16.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313,065 |
| Average Volume | 145,346 |
| Open | 1,790.00 |
| Previous Close | 1,840.50 |
| Day's Range | 1,735.00 - 1,839.50 |
| 52-Week Range | 1,157.00 - 1,878.50 |
| Beta | 0.80 |
| RSI | 68.94 |
| Earnings Date | Nov 6, 2025 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants t...
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDTCompany ParticipantsAnthony Pagano - Executive VP &...
GMAB: Guggenheim Upgrades Genmab's Rating to 'Buy' on September 24, 2025 | GMAB Stock News
GMAB: Guggenheim Upgrades Genmab's Rating to 'Buy' on September 24, 2025 | GMAB Stock News
Genmab (GMAB) Upgraded to Buy by Guggenheim Amid Growth Prospects
Genmab (GMAB) Upgraded to Buy by Guggenheim Amid Growth Prospects
Genmab (GMAB) Ownership Update: Orbis Manages Over 5% Stake
Genmab (GMAB) Ownership Update: Orbis Manages Over 5% Stake
Guggenheim Upgrades Genmab (GMAB) to Buy, Sets Price Target at $43 | GMAB Stock News
Guggenheim Upgrades Genmab (GMAB) to Buy, Sets Price Target at $43 | GMAB Stock News
Genmab upgraded at Guggenheim; says Darzalex related growth concerns are overblown
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Mar...
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Genmab is expanding beyond royalties with strong drug sales, a deep oncology pipeline, and $2.9B in cash, supporting long-term growth. Learn why GMAB stock is a buy.
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl...
Genmab: A Matter Of Time
Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The inc...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting
AbbVie (ABBV) stock in focus as the company posts new data from a mid-stage trial for its lymphoma drug epcoritamab developed with Genmab. Read more here.
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) i...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will part...